Assembly Biosciences develops therapeutic candidates for viral diseases. They have several products in clinical trials: ABI-5366 for recurrent genital herpes, ABI-1179 for recurrent genital herpes, and ABI-6250 for hepatitis delta virus. They also develop ABI-4334 for hepatitis B virus and other treatments targeting transplant-related herpesviruses and HBV/HDV. The company has partnerships with Gilead Sciences and BeiGene.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 0.8 |